RecruitingPhase 3NCT05477589
Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML
Studying Inherited acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Vastra Gotaland Region
- Principal Investigator
- Karin Mellgren, Prof. MDSahlgrenska University Hospital
- Intervention
- busulfan, cyclophosphamide and melphalan, BuCyMel(drug)
- Enrollment
- 170 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2031
Study locations (17)
- L'Hôpital Universitaire des Enfants Reine Fabiola (HUDERF), Brussels, Belgium
- Cliniques Universitaires Saint-Luc (CUSL), Brussels, Belgium
- Department of Pediatric Hematology, Oncology and SCT, Ghent University Hospital, Ghent, Belgium
- University Hospital Leuven, Leuven, Belgium
- Centre Hospitalier Régional de la Citadelle (CHR)/CHU Liège, Liège, Belgium
- Paediatric Stem Cell Transplant and Immune Deficiency, Department of Pediatric and Adolescent Medicine, Section 4072, Rigshospitalet University Hospital of Copenhagen, Copenhagen, Denmark
- Division of Hematology, Oncology, and Stem Cell Transplantation, The New Children's Hospital, Helsinki University Hospital, Helsinki, Finland
- Department of Pediatrics and Adolescent Medicine, Hong King Children's Hospital, Hong Kong, Hong Kong
- Schneider Children's Medical Center of Israel, Petah Tikva, Israel
- Vilnius University Hospital Santaros Klinikos Center for Pediatric Oncology and Hematology, Vilnius, Lithuania
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
- Department of Pediatric Hematology and Oncology, Oslo University HospitalOslo University Hospital, Oslo, Norway
- Stemcelltransplant unit Hospital Niño Jesús, Madrid, Spain
- Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden
- Barncancercentrum, avdelning 64, Skane University Hospital, Lund, Sweden
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05477589 on ClinicalTrials.govOther trials for Inherited acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06782542Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction ChemotherapyJustin Watts, MD
- RECRUITINGPHASE2NCT06557421De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding PatientsInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07130695Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and ConsolidationVirginia Commonwealth University
- RECRUITINGPHASE1NCT07320235Imetelstat Combinations in Relapsed AMLDouglas Tremblay
- RECRUITINGPHASE2NCT06904482Co-Transplant of an Unmodified Haplo-Identical Graft With Cord BloodCase Comprehensive Cancer Center
- RECRUITINGNCT07163728Leptin: A Marker for AML Chemo-SensitivityFujian Medical University Union Hospital
- RECRUITINGNANCT06697600A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their CaregiversUniversity of Rochester
- RECRUITINGPHASE2, PHASE3NCT06972641Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell TransplantationRuijin Hospital